EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)
Abstract
Authors
A. Aburmilah Y. Hammas N. Nouri N. Oulmane M. Yala A. Yala